실적분석 2026년 8월 14일

Outlook Therapeutics ($OTLK) FY2026 Q3 Earnings Analysis — Revenue and Adjusted EPS Both Miss Estimates, Shares Weaken After-Hours

Earnings Scorecard

Revenue: $9,000 (approximately -99% year-over-year, vs. $970,000 estimate) ❌ Miss

EPS: Adjusted -$0.09 (vs. -$0.07 estimate) ❌ Miss

Guidance: None provided — no quarterly or annual financial outlook (only the U.S. late-2026 launch plan and the >$500 million U.S. annual revenue potential by 2030 were referenced)

Stock reaction: After-hours -5.57% ($0.84) — as of 08-14 20:50 KST

Positives

FDA approval: Secured the only approved ophthalmic bevacizumab (Lytenava)

Narrower adjusted loss: Adjusted net loss attributable to common shareholders reduced to $10.9 million

Launch funding: Raised approximately $51.1 million in net proceeds

The U.S. FDA approval of Lytenava, a treatment for wet age-related macular degeneration, was the central narrative this quarter. The adjusted loss also narrowed from a year ago, and a post-quarter capital raise strengthened the funding base for the U.S. launch.

Negatives

Near-zero revenue: Q3 revenue of $9,000 fell well short of both estimates and the prior-year period

Adjusted EPS miss: Adjusted loss of -$0.09 per share came in worse than the -$0.07 estimate

Share dilution burden: Issued approximately 55.56 million new shares alongside warrants

Early European sales also remain small, leaving revenue essentially empty. The $20.3 million GAAP net loss attributable to common shareholders remains substantial, and pre-launch financing has translated into meaningful shareholder dilution.

What Management Said

Management views the U.S. approval of Lytenava as a company turning point and stated it will focus on building out experienced retinal-field personnel, executing the U.S. launch by late 2026, and securing access to insurance and pricing. The tone suggested a deliberate shift in attention away from quarterly/annual financial guidance toward the longer-term commercialization story.

Market Reaction and Forward Watchpoints

Shares reacted weaker as the revenue gap and dilution from the capital raise outweighed the already well-known approval catalyst.

Whether the U.S. commercial launch on schedule in late 2026 and the pace of early prescriptions and insurance coverage

Progress on the fixed-code application for insurance billing by the October 1 deadline and securing reimbursement

Whether sales in key European markets recover and quarterly revenue returns to a meaningful run rate